<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01388946</url>
  </required_header>
  <id_info>
    <org_study_id>149/27.5.10 &amp; Σ-147/03-08-10</org_study_id>
    <nct_id>NCT01388946</nct_id>
  </id_info>
  <brief_title>Analgesia in Laparoscopic Cholecystectomy</brief_title>
  <official_title>Perioperative Ropivacaine Wound Infusion in Laparoscopic Cholecystectomy. A Randomized Controlled Double-blind Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Athens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Athens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesis is that perioperative infusion of 0.75 ropivacaine in patients
      undergoing laparoscopic cholecystectomy may modify the intensity of postoperative pain or the
      analgesic consumption during the first 24 hours.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients scheduled for laparoscopic cholecystectomy were randomly assigned to receive via a
      subcutaneous catheter 2 ml per hour of 0.75 ropivacaine or same volume of normal saline. The
      catheter was inserted after induction of general anesthesia and before beginning of surgery
      and continued for the first 24 postoperative hours. The solutions were administered by means
      of an elastomeric pump. Before induction of anesthesia metoclopramide 10 mg, ranitidine 50 mg
      and droperidol 0.75 mg were given intravenously. In the operating room the routine monitoring
      was applied. Anesthesia was induced with thiopental 5-6 mg/kg, fentanyl 2 μg/kg, and
      rocuronium 0.6 mg/kg, and maintained with sevoflurane 1-1.5 Minimum Alveolar Concentration
      (MAC) in a nitrous oxide/oxygen mixture. After induction of anesthesia diclofenac 75 mg I.V
      was given within 30 min. Before wound closure each hole was infiltrated with 2 ml of
      ropivacaine 0.75 or normal saline. At the end of surgery neuromuscular block was reversed
      with sugammadex 2 mg/kg., the patient was extubated and transferred to the Post-anesthesia
      Care Unit (PACU).

      Intra-operatively, the intra-abdominal pressure, the rate of carbon dioxide insufflation and
      the total amount of carbon dioxide insufflated are recorded every 5 minutes.

      Besides the ropivacaine infusion in the operative site, postoperative analgesia is assured in
      the PACU with paracetamol 1 gr and tramadol 100 mg if Visual Analogue Scale (VAS) score is
      above 40 mm.In the ward Lonarid tablets are given instead.

      VAS values and analgesic consumption are recorded in the PACU, and 2, 4, 8, 24 and 48 hours
      after surgery.

      The catheter is removed 24 hours after surgery. One and three months after surgery patients
      are interviewed by phone for the presence of pain due to surgery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VAS Score Changes ( Cough) During 24 h Postoperatively</measure>
    <time_frame>24 h</time_frame>
    <description>Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Scores in the Postoperative Care Unit (PACU) at Rest</measure>
    <time_frame>in PACU</time_frame>
    <description>Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Scores at Rest 2 h Postoperatively</measure>
    <time_frame>2 h postoperatively</time_frame>
    <description>Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Scores at Rest 4 h Postoperatively</measure>
    <time_frame>4 h</time_frame>
    <description>Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Scores at Rest 8 h Postoperatively</measure>
    <time_frame>8 h</time_frame>
    <description>Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Scores at Rest 24 h Postoperatively</measure>
    <time_frame>24h</time_frame>
    <description>Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Scores at Rest 48 h Postoperatively</measure>
    <time_frame>48 h</time_frame>
    <description>Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Scores During Cough in the PACU</measure>
    <time_frame>PACU</time_frame>
    <description>Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Scores During Cough 2 h Postoperatively</measure>
    <time_frame>2 h</time_frame>
    <description>Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Scores During Cough 4 h Postoperatively</measure>
    <time_frame>4 h</time_frame>
    <description>Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Scores During Cough 8 h Postoperatively</measure>
    <time_frame>8 h</time_frame>
    <description>Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Scores During Cough 48 h Postoperatively</measure>
    <time_frame>48 h</time_frame>
    <description>Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic Pain</measure>
    <time_frame>one month postoperatively</time_frame>
    <description>Number and incidence of patients with persisting pain (burning pain, loss of sensation) one month postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic Pain</measure>
    <time_frame>three months</time_frame>
    <description>Number and incidence of patients with persisting pain (burning pain, loss of sensation) three month postoperatively</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Pain, Postoperative</condition>
  <condition>Chronic Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Ropivacaine 0.75</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuous infusion of ropivacaine 7.5 mg/ml, 2 ml/h for 24 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Continuous infusion of normal saline 2 ml/h for 24 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine 0.75</intervention_name>
    <arm_group_label>Ropivacaine 0.75</arm_group_label>
    <other_name>Naropeine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <arm_group_label>Normal saline</arm_group_label>
    <other_name>0.9% saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 30-70 years American Society of Anesthesiology (ASA) physical status
             I-III

          -  Scheduled for laparoscopic cholecystectomy

        Exclusion Criteria:

          -  Patients with chronic pain and/or on analgesics for the last month,

          -  Patients with central nervous, kidney and liver disease, or allergy to local
             anesthetics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emilia Vassi</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Savvas Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Anesthesia, St Savas Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11522</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aretaieio Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2011</study_first_submitted>
  <study_first_submitted_qc>July 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2011</study_first_posted>
  <results_first_submitted>May 6, 2015</results_first_submitted>
  <results_first_submitted_qc>July 5, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 6, 2016</results_first_posted>
  <last_update_submitted>July 5, 2016</last_update_submitted>
  <last_update_submitted_qc>July 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Athens</investigator_affiliation>
    <investigator_full_name>Argyro Fassoulaki</investigator_full_name>
    <investigator_title>MD, PhD, DEAA</investigator_title>
  </responsible_party>
  <keyword>acute postoperative pain</keyword>
  <keyword>late pain</keyword>
  <keyword>chronic pain</keyword>
  <keyword>wound irrigation with local anesthetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to share data. The study has been published</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ropivacaine 0.75</title>
          <description>Continuous infusion of ropivacaine 7.5 mg/ml, 2 ml/h for 24 hours
Ropivacaine 0.75</description>
        </group>
        <group group_id="P2">
          <title>Normal Saline</title>
          <description>Continuous infusion of normal saline 2 ml/h for 24 hours
Normal saline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>To assess differences in patients’ characteristics between the two groups, two-independent samples t-tests for normally distributed variables (age and duration of surgery) and Mann-Whitney tests for abnormally distributed variables (BMI and CO2 total volume consumed) were carried out.</population>
      <group_list>
        <group group_id="B1">
          <title>Ropivacaine 0.75</title>
          <description>Continuous infusion of ropivacaine 7.5 mg/ml, 2 ml/h for 24 hours
Ropivacaine 0.75</description>
        </group>
        <group group_id="B2">
          <title>Normal Saline</title>
          <description>Continuous infusion of normal saline 2 ml/h for 24 hours
Normal saline</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
            <count group_id="B2" value="55"/>
            <count group_id="B3" value="110"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51" spread="11.2"/>
                    <measurement group_id="B2" value="48" spread="12.5"/>
                    <measurement group_id="B3" value="50" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Greece</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>VAS Score Changes ( Cough) During 24 h Postoperatively</title>
        <description>Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.</description>
        <time_frame>24 h</time_frame>
        <population>Fifty patients in the Ropivacaine group were analyzed for the primary (VAS score at cough) and secondary outcomes 24 hours postoperatively. One patient presented ileus after the first 24 h and was not assessed for pain 48 h after surgery</population>
        <group_list>
          <group group_id="O1">
            <title>Ropivacaine 0.75</title>
            <description>Continuous infusion of ropivacaine 7.5 mg/ml, 2 ml/h for 24 hours
Ropivacaine 0.75</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Continuous infusion of normal saline 2 ml/h for 24 hours
Normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>VAS Score Changes ( Cough) During 24 h Postoperatively</title>
          <description>Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.</description>
          <population>Fifty patients in the Ropivacaine group were analyzed for the primary (VAS score at cough) and secondary outcomes 24 hours postoperatively. One patient presented ileus after the first 24 h and was not assessed for pain 48 h after surgery</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" spread="26"/>
                    <measurement group_id="O2" value="31" spread="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Scores in the Postoperative Care Unit (PACU) at Rest</title>
        <description>Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.</description>
        <time_frame>in PACU</time_frame>
        <population>Below is the mean and standard deviation of the VAS scores in PACU at rest Fifty patients in the Ropivacaine group were analyzed for the primary and secondary outcomes 24 hours postoperatively. One patient presented ileus after the first 24 h and was not assessed for pain 48 h after surgery</population>
        <group_list>
          <group group_id="O1">
            <title>Ropivacaine 0.75</title>
            <description>Continuous infusion of ropivacaine 7.5 mg/ml, 2 ml/h for 24 hours
Ropivacaine 0.75</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Continuous infusion of normal saline 2 ml/h for 24 hours
Normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Scores in the Postoperative Care Unit (PACU) at Rest</title>
          <description>Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.</description>
          <population>Below is the mean and standard deviation of the VAS scores in PACU at rest Fifty patients in the Ropivacaine group were analyzed for the primary and secondary outcomes 24 hours postoperatively. One patient presented ileus after the first 24 h and was not assessed for pain 48 h after surgery</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" spread="25"/>
                    <measurement group_id="O2" value="46" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Scores at Rest 2 h Postoperatively</title>
        <description>Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.</description>
        <time_frame>2 h postoperatively</time_frame>
        <population>Fifty patients in the Ropivacaine group were analyzed for the primary and secondary outcomes 24 hours postoperatively. One patient presented ileus after the first 24 h and was not assessed for pain 48 h after surgery.
Below are the VAS values (mean and standard deviation) 2 h postoperatively at rest</population>
        <group_list>
          <group group_id="O1">
            <title>Ropivacaine 0.75</title>
            <description>Continuous infusion of ropivacaine 7.5 mg/ml, 2 ml/h for 24 hours
Ropivacaine 0.75</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Continuous infusion of normal saline 2 ml/h for 24 hours
Normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Scores at Rest 2 h Postoperatively</title>
          <description>Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.</description>
          <population>Fifty patients in the Ropivacaine group were analyzed for the primary and secondary outcomes 24 hours postoperatively. One patient presented ileus after the first 24 h and was not assessed for pain 48 h after surgery.
Below are the VAS values (mean and standard deviation) 2 h postoperatively at rest</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" spread="21"/>
                    <measurement group_id="O2" value="30" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Scores at Rest 4 h Postoperatively</title>
        <description>Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.</description>
        <time_frame>4 h</time_frame>
        <population>Fifty patients in the Ropivacaine group were analyzed for the primary and secondary outcomes 24 hours postoperatively. One patient presented ileus after the first 24 h and was not assessed for pain 48 h after surgery Below are the VAS values (mean and standard deviation) at rest 4 h postoperatively</population>
        <group_list>
          <group group_id="O1">
            <title>Ropivacaine 0.75</title>
            <description>Continuous infusion of ropivacaine 7.5 mg/ml, 2 ml/h for 24 hours
Ropivacaine 0.75</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Continuous infusion of normal saline 2 ml/h for 24 hours
Normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Scores at Rest 4 h Postoperatively</title>
          <description>Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.</description>
          <population>Fifty patients in the Ropivacaine group were analyzed for the primary and secondary outcomes 24 hours postoperatively. One patient presented ileus after the first 24 h and was not assessed for pain 48 h after surgery Below are the VAS values (mean and standard deviation) at rest 4 h postoperatively</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" spread="18"/>
                    <measurement group_id="O2" value="22" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Scores at Rest 8 h Postoperatively</title>
        <description>Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.</description>
        <time_frame>8 h</time_frame>
        <population>Fifty patients in the Ropivacaine group were analyzed for the primary and secondary outcomes 24 hours postoperatively. One patient presented ileus after the first 24 h and was not assessed for pain 48 h after surgery Below are the VAS values (mean and standard deviation) at rest 8 h postoperatively</population>
        <group_list>
          <group group_id="O1">
            <title>Ropivacaine 0.75</title>
            <description>Continuous infusion of ropivacaine 7.5 mg/ml, 2 ml/h for 24 hours
Ropivacaine 0.75</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Continuous infusion of normal saline 2 ml/h for 24 hours
Normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Scores at Rest 8 h Postoperatively</title>
          <description>Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.</description>
          <population>Fifty patients in the Ropivacaine group were analyzed for the primary and secondary outcomes 24 hours postoperatively. One patient presented ileus after the first 24 h and was not assessed for pain 48 h after surgery Below are the VAS values (mean and standard deviation) at rest 8 h postoperatively</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" spread="22"/>
                    <measurement group_id="O2" value="20" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Scores at Rest 24 h Postoperatively</title>
        <description>Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.</description>
        <time_frame>24h</time_frame>
        <population>Fifty patients in the Ropivacaine group were analyzed for the primary and secondary outcomes 24 hours postoperatively. One patient presented ileus after the first 24 h and was not assessed for pain 48 h after surgery Below are the VAS values (mean and standard deviation) at rest 24 h postoperatively</population>
        <group_list>
          <group group_id="O1">
            <title>Ropivacaine 0.75</title>
            <description>Continuous infusion of ropivacaine 7.5 mg/ml, 2 ml/h for 24 hours
Ropivacaine 0.75</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Continuous infusion of normal saline 2 ml/h for 24 hours
Normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Scores at Rest 24 h Postoperatively</title>
          <description>Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.</description>
          <population>Fifty patients in the Ropivacaine group were analyzed for the primary and secondary outcomes 24 hours postoperatively. One patient presented ileus after the first 24 h and was not assessed for pain 48 h after surgery Below are the VAS values (mean and standard deviation) at rest 24 h postoperatively</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" spread="16"/>
                    <measurement group_id="O2" value="15" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Scores at Rest 48 h Postoperatively</title>
        <description>Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.</description>
        <time_frame>48 h</time_frame>
        <population>50 patients in the Ropivacaine group were analyzed for the primary and secondary outcomes 24 hours postoperatively. 1 patient in this group presented ileus after the first 24 h assessment, remaining 49 patients for assessment at 48 hours postoperatively Below are the VAS values (mean and standard deviation) at rest 48 hours postoperatively</population>
        <group_list>
          <group group_id="O1">
            <title>Ropivacaine 0.75</title>
            <description>Continuous infusion of ropivacaine 7.5 mg/ml, 2 ml/h for 24 hours
Ropivacaine 0.75</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Continuous infusion of normal saline 2 ml/h for 24 hours
Normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Scores at Rest 48 h Postoperatively</title>
          <description>Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.</description>
          <population>50 patients in the Ropivacaine group were analyzed for the primary and secondary outcomes 24 hours postoperatively. 1 patient in this group presented ileus after the first 24 h assessment, remaining 49 patients for assessment at 48 hours postoperatively Below are the VAS values (mean and standard deviation) at rest 48 hours postoperatively</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" spread="11"/>
                    <measurement group_id="O2" value="12" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Scores During Cough in the PACU</title>
        <description>Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.</description>
        <time_frame>PACU</time_frame>
        <population>Fifty patients in the Ropivacaine group were analyzed for the primary and secondary outcomes 24 hours postoperatively. One patient presented ileus after the first 24 h and was not assessed for pain 48 h after surgery Below are the VAS values (mean and standard deviation) during cough in PACU</population>
        <group_list>
          <group group_id="O1">
            <title>Ropivacaine 0.75</title>
            <description>Continuous infusion of ropivacaine 7.5 mg/ml, 2 ml/h for 24 hours
Ropivacaine 0.75</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Continuous infusion of normal saline 2 ml/h for 24 hours
Normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Scores During Cough in the PACU</title>
          <description>Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.</description>
          <population>Fifty patients in the Ropivacaine group were analyzed for the primary and secondary outcomes 24 hours postoperatively. One patient presented ileus after the first 24 h and was not assessed for pain 48 h after surgery Below are the VAS values (mean and standard deviation) during cough in PACU</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" spread="27"/>
                    <measurement group_id="O2" value="55" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Scores During Cough 2 h Postoperatively</title>
        <description>Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.</description>
        <time_frame>2 h</time_frame>
        <population>Fifty patients in the Ropivacaine group were analyzed for the primary and secondary outcomes 24 hours postoperatively. One patient presented ileus after the first 24 h and was not assessed for pain 48 h after surgery Below are the VAS values (mean and standard deviation) during cough 2 h postoperatively</population>
        <group_list>
          <group group_id="O1">
            <title>Ropivacaine 0.75</title>
            <description>Continuous infusion of ropivacaine 7.5 mg/ml, 2 ml/h for 24 hours
Ropivacaine 0.75</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Continuous infusion of normal saline 2 ml/h for 24 hours
Normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Scores During Cough 2 h Postoperatively</title>
          <description>Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.</description>
          <population>Fifty patients in the Ropivacaine group were analyzed for the primary and secondary outcomes 24 hours postoperatively. One patient presented ileus after the first 24 h and was not assessed for pain 48 h after surgery Below are the VAS values (mean and standard deviation) during cough 2 h postoperatively</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" spread="27"/>
                    <measurement group_id="O2" value="55" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Scores During Cough 4 h Postoperatively</title>
        <description>Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.</description>
        <time_frame>4 h</time_frame>
        <population>Fifty patients in the Ropivacaine group were analyzed for the primary and secondary outcomes 24 hours postoperatively. One patient presented ileus after the first 24 h and was not assessed for pain 48 h after surgery Below are the VAS values (mean and standard deviation) during cough 4 h postoperatively</population>
        <group_list>
          <group group_id="O1">
            <title>Ropivacaine 0.75</title>
            <description>Continuous infusion of ropivacaine 7.5 mg/ml, 2 ml/h for 24 hours
Ropivacaine 0.75</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Continuous infusion of normal saline 2 ml/h for 24 hours
Normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Scores During Cough 4 h Postoperatively</title>
          <description>Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.</description>
          <population>Fifty patients in the Ropivacaine group were analyzed for the primary and secondary outcomes 24 hours postoperatively. One patient presented ileus after the first 24 h and was not assessed for pain 48 h after surgery Below are the VAS values (mean and standard deviation) during cough 4 h postoperatively</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" spread="19"/>
                    <measurement group_id="O2" value="34" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Scores During Cough 8 h Postoperatively</title>
        <description>Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.</description>
        <time_frame>8 h</time_frame>
        <population>Fifty patients in the Ropivacaine group were analyzed for the primary and secondary outcomes 24 hours postoperatively. One patient presented ileus after the first 24 h and was not assessed for pain 48 h after surgery Below are the VAS values (mean and standard deviation) 8 h postoperatively</population>
        <group_list>
          <group group_id="O1">
            <title>Ropivacaine 0.75</title>
            <description>Continuous infusion of ropivacaine 7.5 mg/ml, 2 ml/h for 24 hours
Ropivacaine 0.75</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Continuous infusion of normal saline 2 ml/h for 24 hours
Normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Scores During Cough 8 h Postoperatively</title>
          <description>Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.</description>
          <population>Fifty patients in the Ropivacaine group were analyzed for the primary and secondary outcomes 24 hours postoperatively. One patient presented ileus after the first 24 h and was not assessed for pain 48 h after surgery Below are the VAS values (mean and standard deviation) 8 h postoperatively</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" spread="25"/>
                    <measurement group_id="O2" value="34" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Scores During Cough 48 h Postoperatively</title>
        <description>Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.</description>
        <time_frame>48 h</time_frame>
        <population>Fifty patients in the Ropivacaine group were analyzed for the primary and secondary outcomes 24 hours postoperatively. One patient in this group presented ileus after the first 24 h and was not assessed for pain 48 h after surgery Below are the VAS values (mean and standard deviation) during cough 48 h postoperatively</population>
        <group_list>
          <group group_id="O1">
            <title>Ropivacaine 0.75</title>
            <description>Continuous infusion of ropivacaine 7.5 mg/ml, 2 ml/h for 24 hours
Ropivacaine 0.75</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Continuous infusion of normal saline 2 ml/h for 24 hours
Normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Scores During Cough 48 h Postoperatively</title>
          <description>Visual Analogue Scale (VAS) measuring pain intensity (mm) with total range 0-100 and with 0 representing no pain and 100 representing possible worst pain.</description>
          <population>Fifty patients in the Ropivacaine group were analyzed for the primary and secondary outcomes 24 hours postoperatively. One patient in this group presented ileus after the first 24 h and was not assessed for pain 48 h after surgery Below are the VAS values (mean and standard deviation) during cough 48 h postoperatively</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" spread="17"/>
                    <measurement group_id="O2" value="26" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chronic Pain</title>
        <description>Number and incidence of patients with persisting pain (burning pain, loss of sensation) one month postoperatively</description>
        <time_frame>one month postoperatively</time_frame>
        <population>Below the number of patients with pain one month postoperatively For the chronic pain assessment in the control group we had two dropouts as contact for two patients was not feasible.</population>
        <group_list>
          <group group_id="O1">
            <title>Ropivacaine 0.75</title>
            <description>Continuous infusion of ropivacaine 7.5 mg/ml, 2 ml/h for 24 hours
Ropivacaine 0.75</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Continuous infusion of normal saline 2 ml/h for 24 hours
Normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Chronic Pain</title>
          <description>Number and incidence of patients with persisting pain (burning pain, loss of sensation) one month postoperatively</description>
          <population>Below the number of patients with pain one month postoperatively For the chronic pain assessment in the control group we had two dropouts as contact for two patients was not feasible.</population>
          <units>number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chronic Pain</title>
        <description>Number and incidence of patients with persisting pain (burning pain, loss of sensation) three month postoperatively</description>
        <time_frame>three months</time_frame>
        <population>Below the number of patients with pain three months postoperatively. For the chronic pain assessment in the control group we had two dropouts as contact for two patients was not feasible.</population>
        <group_list>
          <group group_id="O1">
            <title>Ropivacaine 0.75</title>
            <description>Continuous infusion of ropivacaine 7.5 mg/ml, 2 ml/h for 24 hours
Ropivacaine 0.75</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Continuous infusion of normal saline 2 ml/h for 24 hours
Normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Chronic Pain</title>
          <description>Number and incidence of patients with persisting pain (burning pain, loss of sensation) three month postoperatively</description>
          <population>Below the number of patients with pain three months postoperatively. For the chronic pain assessment in the control group we had two dropouts as contact for two patients was not feasible.</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>According to study design no adverse events were planned to be collected but in case of adverse events these are routinely included in patient's records for 24 hours postoperatively</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ropivacaine 0.75</title>
          <description>Continuous infusion of ropivacaine 7.5 mg/ml, 2 ml/h for 24 hours
Ropivacaine 0.75</description>
        </group>
        <group group_id="E2">
          <title>Normal Saline</title>
          <description>Continuous infusion of normal saline 2 ml/h for 24 hours
Normal saline</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Argyro Fassoulaki</name_or_title>
      <organization>Aretaieo Hospital University of Athens</organization>
      <phone>+30 6936701333</phone>
      <email>fassoula@aretaieio.uoa.gr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

